TORONTO, ON / ACCESSWIRE / August 26, 2019 / Stans Energy Corp. (TSXV:HRE) (OTC:HREEF) (“Stans” or the “Company”) feels obligated to clarify its position and address our shareholders concerns regarding the Tribunal Award.

While Stans is pleased to be found meritorious by the Tribunal, it is disappointed with the amount awarded as it had claimed in January 2016 for US $219 Million in damages and interest.

The Respondent, Kyrgyz Republic, has a mandatory few months to comply with the ruling or proceed with set-aside proceedings through UK courts, jurisdiction of our Arbitration.

Stans has right to proceed with its own proceedings to protect its interest and we are addressing this issue. Our legal team will provide us with a detailed report with a thorough analysis of the ruling and advice. As soon as we make a decision based on these findings the public will be informed of our next steps.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Stans Energy

Stans Energy Corp. is a resource development company focused on advancing rare and specialty metals properties and processing technologies. Stans is now transitioning to become a supplier of materials and technologies that will assist in satisfying the future energy supply, storage and transmission needs of the world. Previously, the Company acquired, among other things, the right to mine the past producing rare earth mine, Kutessay II, in the Kyrgyz Republic. Due to the expropriation actions taken by the Government of the Kyrgyz Republic, the Company is undertaking international arbitration litigation to protect the Company’s rights and recover damages caused by the Republic.

We seek safe harbour.

Contact Details:

Rodney Irwin
Stans Energy Corp
Interim President & CEO
rodney@stansenergy.com
647-426-1865

Boris Aryev
Stan Energy Corp
Chief Operating Officer
boris@stansenergy.com
647-426-1865

FORWARD LOOKING STATEMENTS: This document includes forward-looking statements as well as historical information. Forward-looking statements include, but are not limited to, use of proceeds from the Offering, the completion of the Offering, the continued advancement of the company’s general business development, research development and the company’s development of mineral exploration projects. When used in this press release, the words “will”, “shall”, “anticipate”, “believe”, “estimate”, “expect”, “intent”, “may”, “project”, “plan”, “should” and similar expressions may identify forward-looking statements. Although Stans Energy Corp. believes that their expectations reflected in these forward looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statement. Important factors that could cause actual results to differ from these forward-looking statements include the potential that fluctuations in the marketplace for the sale of minerals, the inability to implement corporate strategies, the ability to obtain financing and other risks disclosed in our filings made with Canadian Securities Regulators.

SOURCE: Stans Energy Corp.

ReleaseID: 557426

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Curaleaf Holdings, Inc. (OTCMKT:CURLF)
Class Period: November 21, 2018 – July 22, 2019
Deadline: October 4, 2019
For more info: www.bgandg.com/curlf

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration (“FDA”); and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

2U, Inc. (NASDAQ:TWOU)
Class Period: February 25, 2019 – July 30, 2019,
Deadline: October 7, 2019
For more info: www.bgandg.com/twou

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) 2U faced increasing competition in online education and particularly regarding graduate programs; (2) 2U faced certain program-specific issues that negatively impacted its performance; (3) as a result, the Company’s business model was not sustainable; (4) 2U would slow its program launches; and (5) consequently, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Evolent Health, Inc. (NYSE:EVH)
Class Period: March 3, 2017 – May 28, 2019
Deadline: October 7, 2019
For more info: www.bgandg.com/evh

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Evolent’s partnership model did not align the Company’s interests with those of its partners, as the model was designed to inflate the Company’s revenue by extracting enormous administrative and management fees at the expense of its operating partners such as Passport; (2) Passport was struggling financially, particularly after Kentucky cut its reimbursement rates, and the partnership between Evolent and Passport was becoming increasingly unsustainable; (3) Evolent was draining Passport of functions, employees and money, to such an extent that Passport was left on the verge of insolvency; (4) Passport was conducting a bidding process for several months to sell itself to prevent liquidation; and (5) consequently, Defendants’ public statements were materially false and/or misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557350

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ:HSDT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Helius securities from November 9, 2017 and April 10, 2019, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/hsdt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

On January 25, 2019, Helius said that it had received a request for additional data and information from the U.S. Food and Drug Administration (the “FDA”) related to the its request for de novo classification and 510(k) clearance of its Portable Neuromodulation Stimulator (PoNS™) device. Following this news, Helius stock dropped $0.48 per share, or roughly 6%, to close at $7.13 on January 25, 2019.

On April 10, 2019, Helius disclosed that the U.S. Food and Drug Administration (“FDA”) had declined the Company’s request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device. The FDA stated that it lacked sufficient data to determine the relative contributions of the device and physical therapy in clinical studies. Following this news, Helius stock dropped $4.11 per share, or more than 66%, to close at $2.10 on April 10, 2019.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) that the clinical study on the use of PoNS did not produce statistically significant results regarding the effectiveness of the treatment; (2) that, as a result, the clinical study did not support the Company’s application for regulatory clearance; (3) that, as a result, the Company was unlikely to receive regulatory approval of PoNS; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/hsdt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Helius you have until September 9, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557335

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Carbonite, Inc. (NASDAQ:CARB)
Class Period: February 7, 2019 – July 25, 2019
Deadline: September 30, 2019
For more info: www.bgandg.com/carb

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Carbonite’s Server Backup VM Edition was of poor quality and technologically flawed; (2) Carbonite was receiving poor reviews and complaints from customers about the Server Backup VM Edition; (3) the poor quality and technological flaws of the Server Backup VM Edition were acting as a “disruptive” factor throughout the Carbonite salesforce and keeping that sales organization from closing opportunistically on several larger deals during fiscal 2019; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Cardinal Health, Inc. (NASDAQ:CAH)
Class Period: March 2, 2015 – May 2, 2018
Deadline: September 30, 2019
For more info: www.bgandg.com/cah

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements by stating that Cordis Corp., a medical device manufacturer that Cardinal Health acquired in March 2015, would benefit from its advanced inventory management and supply chain information technology solutions. The complaint also alleges that Defendants misleadingly represented that Cardinal Health properly “reserve[d] for inventory obsolescence” and that “[i]nventories presented in the consolidated balance sheets [were] net of reserves for excess and obsolete inventory.”

Just Energy Group Inc. (NYSE:JE)
Class Period: November 9, 2017 – July 23, 2019
Deadline: September 30, 2019
For more info: www.bgandg.com/je

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) that the Company experienced customer enrollment and nonpayment issues; (2) that, as a result, the Company was reasonably likely to incur an impairment charge to its accounts receivable; (3) that, as a result, the Company lacked adequate internal control over its financial reporting; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557347

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Diebold Nixdorf, Incorporated (“Diebold” or the “Company”) (NYSE:DBD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Diebold securities from May 4, 2017 and July 4, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/dbd.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing delays in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle; (2) the foregoing issues were negatively impacting the Company’s services business and operations; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 5, 2017, Diebold issued a press release titled “Diebold Nixdorf Adjusts 2017 Financial Outlook” (the “July 2017 Press Release”). The July 2017 Press Release disclosed that the Company expected a wider net loss than indicated in its prior guidance for fiscal 2017, from a range of $50 to $75 million to a range of $110 to $125 million net loss. Diebold attributed the lowered expectations to a delay in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle. Following this news, Diebold’s stock price fell $6.40 per share, or nearly 23%, to close at $21.60 per share on July 5, 2017.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/dbd or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Diebold you have until September 3, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557332

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against EQT Corporation (“EQT” or the “Company”) (NYSE:EQT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired EQT securities purchased between June 19, 2017 and October 24, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/eqt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) land acquired by the Rice Energy merger was not contiguous with the Company’s previously held acreage, which reduced the purported synergy benefits; (2) the purported longer lateral wells were not feasible because of intervening third-party parcels or prior drilling by EQT, Rice, or third parties; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/eqt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in EQT you have until August 26, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 556465

LOS ANGELES, CA / ACCESSWIRE / August 26, 2019 / Compare-autoinsurance.org has released a new blog post that explains why drivers should keep their cars in optimal running condition and how this will help them get lower car insurance rates.

For more info and free car insurance quotes online, visit https://compare-autoinsurance.org/how-to-save-money-by-providing-proper-maintenance-to-your-car/

Car accidents can also happen when the engine has problems or tires suddenly explode at high speed. This will lead to insurance claims and higher future premiums. To avoid these, make sure to perform the following during routine maintenance:

Change the oil. To properly maintain your vehicle, it’s important to know what type of oil it needs: regular or synthetic. Depending on the car make, and model, cars that use regular oil, need a change at ever 7,500 – 10,000 miles, and the ones that use synthetic or a blend of synthetic oil, can last even 15,000 miles.
Inspect and, if needed, change tires. Make sure that tires are inflated to the recommended PSI for the vehicle’s size. Having properly inflated tires not only help to slow their wear and tear, but also improves gas mileage. To find a vehicle’s recommended PSI, check the owner’s manual.
Change the transmission fluid. To keep the car’s transmission working properly, periodically change the transmission fluid. For an automatic car, the transmission fluid is usually changed between 60,000 miles and 100,000 miles, while a manual car the transmission fluid should be changed between 30,000 miles and 100,000 miles.
Change the air filter. The engine air filter is responsible for cleaning the air from the debris as it enters into the engine compartment. If car’s air filter is getting clogged with dirt, the car may suffer from a reduction in fuel economy, lack of power when accelerating, and even damage to the internal components. These can be avoided when changing the air filter every 15,000 to 30,000 miles.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

For more information, please visit https://compare-autoinsurance.org/

“Taking good care of your car will help you save money and avoid accidents”, said Russell Rabichev, Marketing Director of Internet Marketing Company.

Company Name: Internet Marketing Company
Person for contact Name: Gurgu C
Phone Number: (818) 359-3898
Email: cgurgu@internetmarketingcompany.biz
Website: https://compare-autoinsurance.org/

SOURCE: Internet Marketing Company

ReleaseID: 557405

WILMINGTON, DE / ACCESSWIRE / August 26, 2019 / Rigrodsky & Long, P.A.:

Do you own shares of SRC Energy Inc. (NYSE American:SRCI)?
Did you purchase any of your shares prior to August 26, 2019?
Do you think the proposed merger is fair?
Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of SRC Energy Inc. (“SRC Energy” or the “Company”) (NYSE American:SRCI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by PDC Energy, Inc. (“PDC Energy”) (PDCE) in a transaction valued at $1.7 billion. Under the terms of the agreement, shareholders of SRC Energy will receive 0.158 of a PDC Energy share for each share of SRC Energy owned.

If you own common stock of SRC Energy and purchased any shares before August 26, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:
Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com

SOURCE: Rigrodsky & Long, P.A.

ReleaseID: 557424

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Valaris plc (“Valaris” or “the Company”) (NYSE:VAL) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Valaris securities between April 11, 2019 and July 31, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/val.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Valaris was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (2) the foregoing was reasonably likely to have a material negative impact on Valaris’s second quarter 2019 results; (3) the merger leading to Valaris’s establishment could not deliver on its touted benefits; and (4) as a result, Valaris’s public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/val or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss Valaris you have until October 21, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557365